EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study

Harald Hefter iD, Dietmar Rosenthal, Sara Samadzadeh iD

Toxins · 2023

DOI: 10.3390/toxins15100618 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2023. Verfasst von Harald Hefter und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Neurology, University of Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Neuromuscular Agents, Dystonic Disorders, Torticollis. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The objective of this study was to provide evidence from a simple simulation. In patients with focal dystonia, an initial good response to botulinum neurotoxin (BoNT) injections followed by a secondary worsening does not necessarily arise from an antibody-induced secondary treatment failure (NAB-STF), but may stem from a “pseudo”-secondary treatment failure (PSEUDO-STF).

Methods

The simulation of the outcome after BoNT long-term treatment was performed in four steps: 1. The effect of the first single BoNT injection (SI curve) was displayed as a 12-point graph, corresponding to the mean improvement from weeks 1 to 12. 2. The remaining severity of the dystonia during the nth injection cycle was calculated by subtracting the SI curve (weighted by the outcome after n − 1 cycles) from the outcome after week 12 of the (n − 1)th cycle. 3. A graph was chosen (the PRO curve), which represents the progression of the severity of the underlying disease during BoNT therapy. 4. The interaction between the outcome during the nth BoNT cycle and the PRO curve was determined.

Results

When the long-term outcome after n cycles of BoNT injections (applied every 3 months) was simulated as an interactive process, subtracting the effect of the first cycle (weighted by the outcome after n − 1 cycles) and adding the progression of the disease, an initial good improvement followed by secondary worsening results. This long-term outcome depends on the steepness of the progression and the duration of action of the first injection cycle. We termed this response behavior a “pseudo”-secondary treatment failure, as it can be compensated via a dose increase.

Conclusion

A secondary worsening following an initial good response in BoNT therapy of focal dystonia might not necessarily indicate neutralizing antibody induction but could stem from a “PSEUDO”-STF (a combination of good response behavior and progression of the underlying disease). Thus, an adequate dose adaptation must be conducted before diagnosing a secondary treatment failure in the strict sense.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ANeuromuscular AgentsDystonic DisordersTorticollisHumansTreatment FailureNeurotoxinsDisease Progression

Stichwörter der Autor:innen

duration of botulinum toxin actionfocal dystonialong-term outcome of botulinum neurotoxin therapyneutralizing antibodiessecondary treatment failuresimulation

Substanzen

Botulinum Toxins, Type ANeuromuscular AgentsNeurotoxins

Autor:innen und Institutionen

  • Departments of Neurology, University of Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany.
  • Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Unverstät zu Berlin, Experimental and Clinical Research Center, 13125 Berlin, Germany.
  • Department of Regional Health Research and Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark.
  • Department of Neurology, Slagelse Hospital, 4200 Slagelse, Denmark.

ORCID-Profile: Harald Hefter, Sara Samadzadeh

Zitieren

APA

Hefter, H., Rosenthal, D., & Samadzadeh, S. (2023). “Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study. Toxins. https://doi.org/10.3390/toxins15100618

Vancouver

Hefter H, Rosenthal D, Samadzadeh S. “Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study. Toxins. 2023. doi:10.3390/toxins15100618

BibTeX
@article{Hefter2023,
  author = {Hefter, Harald and Rosenthal, Dietmar and Samadzadeh, Sara},
  title = {“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study},
  journal = {Toxins},
  year = {2023},
  doi = {10.3390/toxins15100618}
}
Kostenlos starten →